



Insights into the identification of a molecular signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-derived motor neurons and exosomes

Mafalda Rizzuti¹ · Valentina Melzi¹ · Delia Gagliardi² · Davide Resnati² · Megi Meneri¹ · Laura Dioni³ · Pegah Masrori^{4,5} · Nicole Hersmus⁴ · Koen Poesen⁶ · Martina Locatelli² · Fabio Biella² · Rosamaria Silipigni⁷ · Valentina Bollati³ · Nereo Bresolin^{1,2} · Giacomo Pietro Comi^{1,2,8} · Philip Van Damme^{4,5} · Monica Nizzardo¹ · Stefania Corti^{1,2}

Received: 5 November 2021 / Revised: 18 February 2022 / Accepted: 21 February 2022
© The Author(s) 2022

Abstract

Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disorder characterized by progressive degeneration of motor neurons (MNs). Most cases are sporadic, whereas 10% are familial. The pathological mechanisms underlying the disease are partially understood, but it is increasingly being recognized that alterations in RNA metabolism and deregulation of microRNA (miRNA) expression occur in ALS. In this study, we performed miRNA expression profile analysis of iPSC-derived MNs and related exosomes from familial patients and healthy subjects. We identified dysregulation of miR-34a, miR-335 and miR-625-3p expression in both MNs and exosomes. These miRNAs regulate genes and pathways which correlate with disease pathogenesis, suggesting that studying miRNAs deregulation can contribute to deeply investigate the molecular mechanisms underlying the disease. We also assayed the expression profile of these miRNAs in the cerebrospinal fluid (CSF) of familial (fALS) and sporadic patients (sALS) and we identified a significant dysregulation of miR-34a-3p and miR-625-3p levels in ALS compared to controls. Taken together, all these findings suggest that miRNA analysis simultaneously performed in different human biological samples could represent a promising molecular tool to understand the etiopathogenesis of ALS and to develop new potential miRNA-based strategies in this new propitious therapeutic era.

Keywords ALS · miRNA · Motor neurons · Exosomes · CSF

Abbreviations

ALS	Amyotrophic lateral sclerosis	fALS	Familial amyotrophic lateral sclerosis
CNS	Central nervous system	miRNAs	MicroRNAs
MNs	Motor neurons	ex-miRNAs	Exosomal microRNAs
sALS	Sporadic amyotrophic lateral sclerosis	CSF	Cerebrospinal fluid
		EVs	Extracellular vesicles

✉ Stefania Corti
stefania.corti@unimi.it

Extended author information available on the last page of the article

FTD	Frontotemporal dementia
HRE	Hexanucleotide repeat expansion
ALSFRS-R	Amyotrophic Lateral Sclerosis Functioning Rating Scale revised
GOI	Genes of interest
HC	Healthy controls
ROC	Relative operating curve
AUC	Area under the curve

Introduction

Amyotrophic lateral sclerosis (ALS) is a complex multifactorial neurodegenerative disease characterized by progressive degeneration of upper and lower motor neurons (MNs) in the brain and spinal cord, leading to progressive muscle paralysis and precocious death [1]. Except for riluzole and, more recently, edaravone, which only modestly increase survival, there is no specific treatment for ALS [2]. Most cases are sporadic (sALS), while only 10% of ALS patients have a family history of disease and exhibit familial ALS (fALS) [1]. The most common genetic causes of ALS are the hexanucleotide repeat expansion (HRE) in *Chromosome 9 open reading frame 72 (C9orf72)* gene [3, 4] and mutations in *superoxide dismutase 1 (SOD1)* [5], *TAR DNA binding protein 43 (TARDBP)* [6] or *Fused in sarcoma (FUS)* [7, 8]. Although several genes have been linked to alterations of protein quality control systems, perturbation of cytoskeletal dynamics in axons and RNA metabolism [9], the pathological mechanisms underlying the disease remain partially understood. Interestingly, both *TARDBP* and *FUS* are involved in RNA processing, including microRNA (miRNA) biogenesis, sequestration or repression [10–18]. MiRNAs are small RNA molecules (~20 nucleotides) that play a key role as endogenous regulators of gene expression. Indeed, they can act at the post-transcriptional level by promoting degradation or translational repression of target messenger RNAs (mRNAs) [19]. Since each miRNA can regulate hundreds of target mRNAs, alterations in the miRNA expression profile can modulate entire gene networks, potentially modifying the pathogenesis of complex syndromes such as neurodegenerative disorders. Interestingly, since approximately 70% of miRNAs are expressed in the brain [20, 21], they are probably involved in the majority of the pathogenetic mechanisms of neurodegeneration [22]. In addition, a small population of miRNAs was detected to circulate in exosomes, small extracellular vesicles (EVs) that can act as mediators of cell-to-cell communication by transferring their cargos to both neighboring and distant cells [23–26].

It has already been described that a dysregulation of miRNA expression occurs in ALS [27–29], but the downstream pathological events associated with MN degeneration have not been completely clarified yet. Here, we aim to

shed light on the common molecular pathways associated with MN degeneration among forms of ALS with different genetic backgrounds. We assessed the miRNA expression profiles of *C9orf72*-, *SOD1*- and *TARDBP*- iPSC-derived MNs, as well as the expression levels of exosomal miRNAs (ex-miRNAs) and we identified a small subset of miRNAs dysregulated in both MNs and exosomes. We further investigated the expression level of these miRNAs in the cerebrospinal fluid (CSF) of ALS patients to identify a miRNA signature shared across different forms of the disease. Noteworthy, altered expression of these molecules in the CSF may represent a useful hallmark of neurodegenerative diseases since miRNAs can closely mirror the physiological and pathological conditions of the central nervous system (CNS) [30].

This is the first work which analyzed simultaneously miRNAs isolated from different human biological samples, such as MNs, exosomes and CSF of different ALS types, offering an innovative approach to investigate the molecular bases of the disease. These findings could provide significant insights into ALS pathogenesis, contributing to translation into the clinic of new potential miRNA-based therapeutic strategies [31–34].

Materials and methods

iPSC generation and differentiation into MNs

Fibroblasts derived from skin biopsies of ALS patients ($n=2$ *SOD1*, p.A4V and p.L144F; $n=2$ *TARDBP*, p.G287S and p.G294V; $n=2$ *C9orf72*, 583 repeats and 917 repeats) and healthy subjects ($n=3$) were reprogrammed into induced Pluripotent Stem Cells (iPSCs) using the CytoTune®-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher Scientific). Karyotype analyses were performed to evaluate genetic stability. iPSCs were stained for specific stem cell markers and differentiated into MNs following the protocol described by Maury and colleagues [35]. The proper phenotype was assessed with immunostaining for typical MN markers.

qPCR analysis

Total RNA was extracted from each MN sample using ReliaPrep™ RNA Cell Miniprep System kit (Promega) and reverse transcribed using the TaqMan® MicroRNA Reverse Transcription Kit (ThermoFisher Scientific) and First Strand cDNA Synthesis kit (GE Healthcare). Exosomes were collected by ultracentrifugation and assessed by the NanoSight NS300 System (Malvern Panalytical). ex-miRNA extraction was performed with the combination of miRNeasy kit and RNeasy Cleanup Kit (Qiagen) and assessed through the 2100 Bioanalyzer RNA system

(Agilent Technologies). Reverse transcription of ex-miRNA was followed by preamplification with TaqMan® Preamp Master Mix kit (ThermoFisher Scientific). Gene and miRNA expression levels were assayed on the 7500 Real Time PCR System (Applied Biosystem). Relative expression quantification was performed by the $2^{-(\Delta\Delta Ct)}$ method, using 18S or RNU6 as reference. All data are mean of triplicates. Only genes and miRNAs with $Ct < 35$ were taken into consideration for subsequent analysis. All the TaqMan® assay IDs are available upon request.

Microfluidic cards assay

TaqMan® Low Density Arrays (TLDA, ThermoFisher Scientific) were used for miRNA profiling. Plates were run on 7900HT Fast Real Time PCR System (Applied Biosystem) and quantification was performed with the Gene Expression Suite Software (ThermoFisher Scientific), using RNU6 as control, automatic baseline settings and a threshold of 0.2. For ex-miRNAs, data were normalized using the global mean method [36].

Bioinformatic analysis

miRTarBase and miRWalk were exploited to identify validated and predicted miRNA target genes and related pathways. Genes identified in both databases were processed with STRING (version 11) to predict functional interactions among targets, setting the threshold at 0.7 for interaction score and excluding interaction predicted by gene fusion. Cytoscape (version 3.7.2) was used to visualize complex miRNA-gene networks as well as functional interactions. GTex database (Release 8 since Aug 26, 2019) was employed to assay the tissue-specificity gene expression levels. Molecular pathway analysis to identify enriched pathways was performed against Reactome (version 72 on Apr 27, 2020) correcting p-values for multiple testing (Benjamini–Hochberg).

MN treatment with miRNA mimics

ALS-MNs were transfected with a combination of mirVana® miRNA mimics hsa-miR-335-3p (MC13018), hsa-miR-335-5p (MC10063), hsa-miR-34a-3p (MC13089) and hsa-miR-34a-5p (MC10063) by using Lipofectamine® RNAiMAX Transfection Kit (ThermoFisher Scientific) to a final total concentration of 15 nM for 48 h.

Analysis of miRNA isolated from CSF

Circulating miRNAs were isolated from 300 μ L of cerebrospinal fluid (CSF) using NucleoSpin® miRNA plasma kit (Macherey Nagel). RT reactions were performed using

10 ng of RNA, preamplified and run on the 7900HT Fast Real Time PCR System (Applied Biosystem). The expression level of each miRNA was normalized to the average levels of hsa-miR-125b [37] and referred to control samples. Relative expression quantification was performed by the $2^{(-\Delta Ct)}$ method, where $\Delta Ct = Ct \text{ miR-X} - Ct \text{ miR-125b}$. All data are mean of triplicates. Only miRNAs with $Ct < 35$ were taken into consideration for the analysis.

Patient evaluation

ALS patients and healthy controls (HC) were recruited at the Neurology Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan and at the Neurology Department of the University Hospitals in Leuven. ALS diagnosis was formulated according to the El Escorial Revised and Awaji-Shima diagnostic criteria and lumbar puncture for CSF collection was performed during the diagnostic assessment. Site and symptom onset were defined according to the first patient-reported weakness, and disease duration was calculated at the time of CSF collection. HC were defined as individuals with possible neurological symptoms, without evidence of underlying neurological disease after an appropriate diagnostic assessment.

Statistical analysis

Two-tailed, unpaired Student's *t* test was employed to compare the mean expression level of miRNAs detected in MNs and exosomes. q-PCR quantification was expressed as mean with SEM. Data were analyzed with GraphPad Prism Version 5. Baseline demographic and clinical features of ALS patients and HC were analyzed through descriptive statistics. After assessing for normality, continuous variables were reported as mean \pm standard deviation (SD) or median and interquartile range [IQR]. Mann–Whitney and Kruskal–Wallis tests were employed to perform between-group comparisons and to compare CSF miRNA levels between ALS and healthy controls, and among disease groups. Receiver Operating Characteristic (ROC) curves were generated and area under the curve (AUC) was calculated to assess accuracy of CSF miRNA levels in discriminating between ALS and controls of between two ALS subgroups. The ratios of levels of CSF miRNAs were calculated for significant pairs [38]. Best cut-off values were calculated with Youden's Index. Univariable binomial logistic regression models were employed to evaluate the association among CSF miRNA levels and the disease. Statistical analysis was performed with GraphPad Prism Version 9.1.

Ethical statement

The studies involving human samples were conducted in accordance with the ethical standards of the Declaration of Helsinki and with national legislation and institutional guidelines. Human fibroblast cell lines were obtained from Eurobiobank with informed consent approved by the ethical committee at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan. All subjects provided written informed consent approved by the local ethical committee for the collection, storage and analysis of CSF samples (0004520, S50354, S55312, S59552). This experimental study was conducted in accordance with the international GLP and GCP guidelines.

Results

Dysregulation of miRNA expression in ALS-MNs affects molecular pathways associated with MN degeneration

miRNA profiling

After generation of iPSCs (Fig. S1, A) and MNs (Fig. S1, B) of healthy individuals and ALS patients carrying *C9orf72*, *SOD1* and *TARDBP* mutations, we profiled the miRNA transcriptome of ALS-MNs by TaqMan® Low Density Arrays (TLDA). We identified a subset of 16 significantly down-regulated miRNAs (Fig. 1A) whose reduced expression was validated by qPCR (Fig. 1B). Interestingly, when *C9orf72*-MNs, *SOD1*-MNs or *TARDBP*-MNs were considered independent biological groups, the profiling data showed that the expression of both miR-34a and miR-335 was reduced in all three MN lines (Table S1, A). This downregulation was validated by RT-PCR for miR-34a-3p, miR-34a-5p (*SOD1*-MNs: $P < 0.05$; *TARDBP*-MNs: $P < 0.05$; *C9orf72*-MNs: $P < 0.05$), miR-335-3p (*TARDBP*-MNs: $P < 0.001$; *C9orf72*-MNs: $P < 0.001$) and miR-335-5p (*TARDBP*-MNs: $P < 0.05$; *C9orf72*-MNs: $P < 0.05$) (Fig. 1C).

Bioinformatics

To identify target genes and related pathways associated with miR-34a-3p, miR-34a-5p, miR-335-3p and miR-335-5p, we employed the miRWalk and miRTarBase databases, which provide a list of validated and predicted miRNAs. We identified 21 genes targeted by at least two of these four miRNAs in both the databases, to obtain the most stringent and reliable dataset (Fig. 2A). Notably, these 21 genes were all targets of miR-34a-5p, while none of them was targeted by miR-335-5p. In particular, 13 out of these 21 genes were targeted by both miR-34a-5p and miR-335-3p,

whereas the remaining 8 genes were targeted by both miR-34a-5p and miR-34a-3p. To predict the functional interactions among these target genes, the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) (Fig. 2B) and miRNA–gene interactions were used, as well as functional connections from STRING were visualized exploiting Cytoscape (Fig. 2C). We queried the Genotype-Tissue Expression (GTEx) database to assay the tissue-specific expression of these 21 genes, focusing on their expression in brain and spinal cord (Fig. 2D). Finally, we employed the Reactome Pathway Database to identify the biological pathways in which these genes are involved. Three hundred forty-three pathways (141 with statistical significance) were hit by at least one of 16 out of 21 genes (Table S2). In particular, the most enriched pathways are mainly involved in neurodegeneration processes, such as intrinsic pathway for apoptosis ($P < 0.001$), programmed cell death ($P < 0.01$), death receptor signaling ($P = 0.05$), cytokine signaling in the immune system ($P < 0.001$) and SUMOylation ($P < 0.01$). Due to the relevance of apoptosis and apoptotic pathways in MN degeneration, we selected *BCL2*, *IL6R*, *MAP3K7*, *PLCG1*, *PPARA* and *PRRC2B* as promising candidates for further investigations. We also investigated *LDHA* due to its very high expression levels in neural tissues. Finally, we investigated *FOXN3* given its crucial role in DNA damage [39] as well as *NUFIP2* for its interaction with FMRP protein, involved in synaptic plasticity [40].

miRNA mimic transfection

We assayed whether synthetic sequences that mimic endogenous miRNAs can functionally rescue miRNA levels and modulate the expression of target genes of interest (GOI). To this end, we transfected ALS-MNs with the four miRNA mimics (Fig. 3A) and assessed the expression of GOI. Overall, our results showed a general dysregulation of almost all the selected target genes in affected MNs compared to controls, with notable differences among the expression levels of these genes in *C9orf72*-, *SOD1*- and *TARDBP*-MNs. However, the administration of miRNA mimics was not able to significantly modulate or completely rescue the expression of GOI (Fig. 3B).


Exosomal miRNA profiling reveals their potential role in intercellular communication

ex-miRNAs profiling

The exosomal nature of EVs isolated from ALS-MN culture media was confirmed by nanoparticle tracking analysis (Fig. 4A). We profiled the expression levels of ex-miRNAs by TLDA. In particular, we found that miR-34a-5p, miR-625-3p and miR-1267 expression was

Fig. 1 miRNA expression profiling of iPSC-derived MNs.

A Volcano plot and list of dysregulated miRNAs. Results are presented enclosing ALS subjects presenting *C9orf72*, *TARDBP* or *SOD1* mutations in a unique biological group ($n=6$) versus controls ($n=3$). The statistically significant downregulated miRNAs are listed in the table. **B** Specific qPCR assays confirmed the downregulation of identified miRNAs in ALS-MNs ($n=6$) compared to controls ($n=3$) ($*P<0.05$, $**P<0.01$, $***P<0.001$, student *t*-test, values represent means + SEM). **C** qPCR assays confirmed the specific reduction of miR-34a-3p, miR-34a-5p, miR-335-3p or miR-335-5p expression in *C9orf72*-MNs, *SOD1*-MNs and *TARDBP*-MNs (at least $n=3$ healthy subjects, *C9orf72*-MNs, *SOD1*-MNs and *TARDBP*-MNs, $*P<0.05$, $***P<0.001$, student *t*-test, values represent means + SEM)



downregulated while miR-629-5p and miR-194-5p levels were upregulated (Fig. 4B). Notably, miR-625-3p expression was always significantly downregulated in *C9orf72*- and *SOD1*-exosomes when considered as independent biological groups (Table S1, B). However, we confirmed by qPCR the dysregulation of ex-miR-625-3p expression only in exosomes isolated from *C9orf72* lines ($P<0.01$)

while *TARDBP* exosomes showed a strong increase in ex-miR-625-3p content ($P<0.01$) (Fig. 4B).

Bioinformatics

To deeply elucidate the role of ex-miR-625-3p as a potential mediator of intercellular communication, we performed

A

Gene	Description
1	ATP5S ATP synthase subunit s, mitochondrial
2	BCL2 BCL2 apoptosis regulator
3	CLIC5 Chloride intracellular channel 5
4	DCTN5 Dynactin subunit 5
5	FAM208A Transcription activation suppressor
6	FOXP3 Forkhead box N3
7	FOXP1 Forkhead box P1
8	IL6R Interleukin 6 receptor
9	KLHDC10 Kelch domain containing 10
10	LDHA Lactate dehydrogenase A
11	MAP3K7 Mitogen-activated protein kinase kinase kinase 7
12	MYC MYC proto-oncogene, bHLH transcription factor
13	NR4A2 Nuclear receptor subfamily 4 group A member 2
14	NUFIP2 Nuclear FMR1 interacting protein 2
15	NUPL2 Nucleoporin 42
16	PLCG1 Phospholipase C gamma 1
17	PPARA Peroxisome proliferator activated receptor alpha
18	PRRC2B Proline rich coiled-coil 2B
19	TGIF2 TGFB induced factor homeobox 2
20	UBAP2 Ubiquitin associated protein 2
21	XIAP X-linked inhibitor of apoptosis






Fig. 2 Bioinformatic analysis of dysregulated miRNAs in *C9orf72*-, *SOD1*- and *TARDBP*-MNs. **A** List of candidate genes identified by bioinformatic analysis. **B** STRING analysis disclosed the predicted functional interactions among target genes. **C** Cytoscape map of the miRNA-target genes interactions and functional connections among target genes. **D** GTEx plot displaying the tissue-specific expression of identified target genes, with a special focus on neural tissues

bioinformatics analysis as previously described for MNs. We identified 15 genes as validated targets of miR-625-3p (Fig. 5A) and processed them with STRING to identify predicted functional interactions (Fig. 5B). We assessed their expression level with the GTEx database (Fig. 5C). Enrichment analysis revealed that 10 out of 15 identified genes were found in the Reactome Pathway Database, with 148 pathways being enriched for at least one of these genes (37 statistically significant, Table S3). Transcriptional regulation by TP53 as well as the role of TP53 in regulating the transcription of cell death genes, together with the cell–cell communication pathway, autophagy and axon guidance stood out significantly. Considering the biological relevance of these pathways together with the expression of selected genes in the CNS and putative interactions among them, we selected *CD47*, *CSNK2A1*, *HSPA8* and *TRIAP1* as promising candidates for further investigations. We include *PEG10* in the group of candidate genes since it has already been investigated as possibly involved in pathological mechanisms underlying ALS [41]. The dysregulation of predicted target genes in almost all ALS-MN lines suggests the potential role of miR-625-3p as a mediator of cell-to-cell communication (Fig. 5D).

A subset of specific miRNAs is dysregulated in ALS-MNs and exosomes

To correlate the miRNA profile data of MNs and related exosomes, we assessed the expression levels of miR-625-3p in ALS-MNs. Data from TLDA experiments showed a reduced expression of miR-625-3p in *C9orf72*- and *SOD1*-MNs, whereas no change was detected in *TARDBP*-MNs (Table S1, A). However, qPCR validation revealed significantly increased expression of this miRNA in *SOD1*-MNs ($P < 0.05$) and *TARDBP*-MNs ($P < 0.001$) (Fig. 6A).

Conversely, we assessed the expression levels of miR-34a-3p, miR-34a-5p, miR-335-3p and miR-335-5p in ALS-exosomes detecting an overall downregulation of all four miRNAs in exosomes released from *C9orf72*-, *SOD1*- and *TARDBP*-MNs compared to control exosomes (Table S1, B). qPCR validation assays revealed a general downregulation of ex-miR-34a-5p (*C9orf72*: $P < 0.05$), ex-miR-335-3p (*SOD1*, *TARDBP*, and *C9orf72*: $P < 0.001$) and ex-miR-335-5p (*SOD1*, *TARDBP*, and *C9orf72*: $P < 0.01$), along with an upregulation of ex-miR-34a-3p in *SOD1*- and *C9orf72*-MNs ($P < 0.001$) (Fig. 6B).

A subset of miRNAs is increased in the CSF of some ALS forms

We investigated the expression of the previously identified miRNAs in the CSF of a cohort of ALS patients and HC. We enrolled 55 ALS patients (sALS, $n = 28$, fALS, $n = 27$), with a mean age of 58.3 ± 11.5 years and 19 HC with a mean age of 52.8 ± 17.5 years ($P = 0.128$). The demographic and clinical features of ALS patients are summarized in Table 1. fALS were carriers of a HRE in *C9orf72* ($n = 13$) and mutations in *SOD1* ($n = 11$) and *TARDBP* ($n = 3$).

We compared CSF miRNA levels between HC and ALS patients and we found increased CSF miR-34a-3p levels in ALS with respect to controls ($P = 0.039$), while other miRNA concentrations did not significantly differ between the two groups (Fig. 7A). Then, we performed between-group comparisons and we found that CSF miR-34a-3p levels were higher in fALS compared to HC ($P = 0.0022$) (Fig. 7B). Moreover, miR-625-3p concentrations were increased in fALS patients as compared with HC ($P = 0.0084$) and sALS patients ($P < 0.0001$) (Fig. 7C).

To test the reliability of CSF miRNAs in identifying ALS subgroups, we performed ROC analysis and binomial logistic regression analyses. ROC analysis showed that miR-34a-3p was able to accurately discriminate ALS (AUC 0.695, $P = 0.039$) and fALS (AUC 0.832, $P = 0.003$) from HC (Fig. 7D) and provided a cutoff value of 0.0188 (sensitivity 60%, specificity 78.6%) and of 0.0159 (sensitivity 92.3%, specificity 66.7%), respectively. CSF miR-34a-3p concentrations higher than 0.0188 predicted ALS diagnosis compared to healthy controls in a binomial regression analysis with an OR = 3.667 (95%CI = 1.064–14.15, $P = 0.046$). CSF miR-34a-3p levels higher than 0.0159 were significantly associated with fALS (OR = 20, 95%CI = 2.86–413.9, $P = 0.009$, Fig. 7D). ROC analysis for CSF miR-625-3p levels showed a moderate accuracy in distinguishing fALS from HC (AUC 0.736, $P = 0.009$) and fALS from sALS group (AUC 0.807, $P = 0.0001$) (Fig. 7E), yielding a cutoff value of 1.462 (sensitivity 64%, specificity 83.3%) and 1.051 (sensitivity 72%, specificity 85.2%), respectively. In a binomial logistic regression analysis, CSF miR-625-3p levels higher than cutoff values were associated with fALS with an OR = 4.653 (95%CI = 1.35–17.63, $P = 0.018$) compared to HC and with fALS with an OR = 11.33 (95%CI = 3.237–48.43, $P = 0.0004$) in comparison with sALS group (Fig. 7E). Finally, we performed a ROC analysis between fALS and HC by using the ratio of levels of miR-625-3p/miR-34a-3p pair. This shows an AUC of 0.731 with a $P = 0.063$ in discriminating fALS from HC (Fig. 7F).




Fig. 3 ALS-MNs transfection with miRNA mimics. **A** qPCR experiments showed the efficiency of transfection with the four selected miRNA mimics in *SOD1*-, *TARDBP*- and *C9orf72*-MNs (at least $n=3$ healthy subjects, *C9orf72*-MNs, *SOD1*-MNs and *TARDBP*-MNs, $*P<0.05$, $**P<0.01$, $***P<0.001$, student *t*-test, values represent means+SEM). **B** qPCR experiments showed the dysregulation of all selected target

genes in *SOD1*-, *TARDBP*- and *C9orf72*-MNs, which could not be completely rescue by the treatment with miRNA-mimics (at least $n=3$ healthy subjects, *C9orf72*-MNs, *SOD1*-MNs and *TARDBP*-MNs, $*P<0.05$, $**P<0.01$, $***P<0.001$, student *t* test, values represent means+SEM)




Fig. 4 Exosomal miRNA profiling. **A** Representative plots of nanoparticle tracking analysis. **B** Volcano plot and list of dysregulated miRNAs identified in exosomes released from ALS-MNs. Results are presented enclosing ALS subjects in a unique biological group ($n=6$) versus controls ($n=3$). qPCR assays confirmed a statisti-

cally significant downregulation of miR-625-3p in exosomes isolated from *C9orf72*-MNs (at least $n=3$, $**P<0.01$), while there is a strong increase of its expression in exosomes derived from *TARDBP*-MNs (at least $n=3$, $**P<0.01$, student *t* test, values represent means + SEM)

Discussion

In the past years, several strategies have been developed to understand both the genetic and molecular mechanisms of ALS, in the attempt to accelerate the discovery of effective treatments [42–45]. Although the pathological events underlying ALS have not been completely clarified yet, defective RNA metabolism is known to be deeply associated with the pathology [46]. Particularly, aberrant miRNA biogenesis has already been related to stress response induced by mutations in the *TARDBP*, *FUS* and *SOD1* genes, providing a potential link between defective miRNA biogenesis and ALS [29, 47, 48]. Interestingly, several studies have already reported a general dysregulation of miRNA expression in both fALS and sALS cases, suggesting that altered miRNA

expression could be a common molecular denominator of multiple forms of ALS [28, 49–55].


We performed miRNA expression profile analysis of iPSC-derived MNs from fALS patients and we demonstrated that miR-34a (3p and 5p) and miR-335 (3p and 5p) were commonly dysregulated in *C9orf72*-, *SOD1*- and *TARDBP*-MNs. Bioinformatic analysis showed that these miRNAs regulate several genes associated with programmed cell death, synaptic plasticity and mitochondrial biogenesis, biological pathways/processes which well correlate with the disease pathogenesis [56]. Indeed, since miRNAs are fundamental for ensuring the physiological homeostasis of tissues, alterations in their expression profile can result in massive impairment of multiple biological pathways [57–59].

We have already described a downregulation of miR-34a expression in iPSC-derived MN progenitors derived from


A

Gene	Description
1 CD2AP	CD2 associated protein
2 CD47	CD47 molecule
3 CPPED1	Calcineurin like phosphoesterase domain containing 1
4 CSNK2A1	Casein kinase 2 alpha 1
5 FKTN	Fukutin
6 HSPA8	Heat shock protein family A (Hsp70) member 8
7 INIP	INTS3 and NABP interacting protein
8 KCNC4	Potassium voltage-gated channel subfamily C member 4
9 MAP2K6	Mitogen-activated protein kinase kinase 6
10 PAPD5	Terminal nucleotidyltransferase 4B
11 PEG10	Paternally expressed 10
12 ROCK2	Rho associated coiled-coil containing protein kinase 2
13 TRIAP1	TP53 regulated inhibitor of apoptosis 1
14 USP1	Ubiquitin specific peptidase 1
15 VEZT	Vezeatin, adherens junctions transmembrane protein

B



C



D




Fig. 5 Bioinformatic analysis of ex-miR-625-3p. **A** List of predicted target genes of miR-625-3p. **B** STRING analysis showed the functional networks among the target genes. **C** GTEx chart illustrates the neural-specific expression of identified target genes. **D** qPCR assays revealed the dysregulation of *CD47*, *CSNK2A1*, *HSPA8*, *PEG10* and *TRIAP1* expression in almost all ALS-MNs (at least $n=3$ healthy subjects, *C9orf72*-MNs, *SOD1*-MNs and *TARDBP*-MNs, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, student t test, values represent means + SEM)

both sALS and fALS patients, supporting its putative role in cell cycle regulation, induction of apoptosis after cell damage and autophagy [53]. Notably, miR-34a is involved in neuronal differentiation and neurogenesis [60] and dysregulation of its expression results in early neurodegeneration in *SOD1* mice [61, 62]. An alteration of miR-34a levels has also been reported in monocytes from ALS patients and mouse models, supporting its involvement in neurodegenerative disorder-related inflammation [37]. Recent evidence has shown that in neurodegenerative diseases, a group of miRNAs, including miR-34a and miR-335, enhances reactive oxygen species generation, perturbing the function of mitochondrial antioxidative enzymes [63]. Moreover, data from ALS subjects' serum revealed a strong reduction in miR-335-5p levels, which correlates with neuronal mitochondrial dysfunction and apoptosis [64]. The role of miR-335-5p in neurodegeneration is further supported by the evidence that downregulation of expression is necessary to maintain hippocampal synaptic plasticity and spatial memory processes in mice [65].

We also assayed the miRNA profiles of exosomes isolated from the culture medium of ALS and healthy MN cultures and we identified a dysregulation of ex-miR-625-3p in ALS-MNs. Indeed, exosomes seem to have a key role in intercellular communication, potentially promoting the progression and the spread of neurodegenerative disorders by modulating cell proliferation, neuronal stability, inflammation and immune response [23, 66]. Bioinformatics analysis revealed that miR-625-3p is predicted to be associated with cell-to-cell communication, autophagy and immune system pathways. Interestingly, miR-625-3p has been identified as a target of long noncoding RNA-p21, which mediates neuroinflammation, oxidative stress, apoptosis and neuronal death [67, 68]. Increased levels of miR-625-3p have been also reported in the muscle tissue of ALS patients [69].

Modulation of one or more miRNAs could be a potential therapeutic strategy. Indeed, restoring the miRNA balance may be particularly interesting since they can modulate multiple pathways simultaneously, but may interact with off-target genes. We successfully used synthetic sequences that mimic endogenous miRNAs to functionally increase the levels of deregulated miRNAs in iPSC-derived MNs. However, our data showed that the modulatory effect of miRNA mimics was not efficacious in rescuing the expression of the target genes, suggesting that changes in target mRNA levels

in affected MNs could not be merely explained by differences in miRNA amount. Alternatively, the treatment needs to be extended in time to permanently change gene target expression or through a direct modulation of crucial target genes. Overall, these experiments together with bioinformatic findings could provide useful insights into specific deregulated pathways in ALS that can represent the ground to understand the pathogenesis and find new therapeutic targets.

There has been an increasing interest in investigating miRNAs in biological fluids as potential disease biomarkers in neurodegenerative disorders. Indeed, they showed exceptional stability in body fluids which allows accurate measurement of their expression levels [70]. Notably, the CSF may be the most promising biological fluid for deep investigation of the pathomechanisms underlying neurodegeneration due to its proximity to the CNS [30]. Different studies have already identified specific subsets of dysregulated miRNAs in serum and CSF samples of patients compared to controls [12, 31, 32, 71–73]. Our data showed an upregulation of CSF miR-34a-3p expression in ALS patients compared to healthy subjects, which has been confirmed by ROC analysis. FALS patients showed significantly higher CSF levels of both miR-34a-3p and miR-625-3p, arguing in favor of the role of these miRNAs in disease pathogenesis. Moreover, miR-625-3p was increased in fALS compared to sALS, suggesting that familial forms might share different pathological mechanisms from sporadic cases. In our cohort, we did not find any significant differences in CSF levels of miR-335-3p and miR-335-5p between ALS and controls, although other studies reported that plasma miR-335 levels accurately distinguish patients with neurodegenerative disorders such as FTD and ALS from controls [74]. Finally, ROC and regression analyses allowed to identify cutoff values for CSF miR-34a-3p and miR-625-3p able to discriminate fALS from both healthy subjects and sporadic patients. Combined analysis using the miR-625-3p/miR-34a-3p pair did not reach significance for discrimination of fALS from controls, likely due to the relatively small sample size. Future studies on broader populations might strengthen the power of these findings and explore the potentiality of these miRNAs as disease biomarkers.

Conclusions

This study shed light on the common pathological mechanisms underlying MN degeneration, confirming the relevance of miRNA modulation in ALS pathogenesis and paving the way for the development of miRNA-based therapeutic approaches aimed at modifying disease pathogenesis. Moreover, we demonstrated that analyzing miRNAs present in CSF could represent a promising tool to define the classification, prognosis, and progression in the context of ALS and eventually in other neurodegenerative diseases.

Fig. 6 Correlation between profiling data of ALS-MNs and released exosomes. **A** qPCR assays confirmed the statistically significant dysregulation of miR-625-3p in *SOD1*-MNs and *TARDBP*-MNs (at least $n=3$, $*P<0.05$, $**P<0.01$, student t test, values represent means + SEM). **B** qPCR experiments validated the deregulation of ex-miR-34a-3p, ex-miR-34a-5p, ex-miR-335-3p and ex-miR-335-5p expression in all exosomes isolated from affected MN lines (at least $n=3$ healthy subjects, *C9orf72*-MNs, *SOD1*-MNs and *TARDBP*-MNs, $*P<0.05$, $**P<0.01$, $***P<0.001$, student t test, values represent means + SEM)




Table 1 Demographic and clinical features of ALS cohort

	Total ($n=55$)	sALS ($n=28$)	fALS ($n=27$)	P -value	<i>C9orf72</i> ($n=13$)	<i>SOD1</i> ($n=11$)	<i>TARDBP</i> ($n=3$)	P -value
Age, years	58.3 ± 11.5	63.9 ± 11	52.5 ± 9	<0.0001	54.6 ± 6.2	48.6 ± 10.8	57 ± 7.8	0.166
Female sex, n (%)	20 (36.4)	11 (39.3)	9 (33.3)	0.646	4 (30.8)	3 (27.3)	2 (66.6)	0.250
Age at onset, years	56.8 ± 11	62 ± 10.5	51.4 ± 8.8	0.0002	53.6 ± 5.9	47.6 ± 11.1	55.3 ± 6.7	0.183
Spinal phenotype, n (%)	38 (69.1)	17 (60.7)	21 (77.8)	0.171	8 (61.5)	10 (90.9)	3 (100)	0.139
Disease duration, months	13 [9–24]	13 [8.3–24]	16 [10–25]	0.838	10 [7–14]	25 [12–42]	16 [16–32]	0.004

Demographic and clinical features of enrolled sALS and fALS patients. Mean ± SD or median [IQR] and number (%), as appropriate
fALS familial amyotrophic lateral sclerosis, *sALS* sporadic amyotrophic lateral sclerosis




Fig. 7 Distribution of miRNA levels in CSF of ALS patients. **A** CSF miR-34a-3p, miR-34a-5p, miR-335-3p, miR-335-5p and miR-625-3p levels in healthy controls (HC) and ALS patients. CSF miR-34a-3p levels are higher in ALS than in HC (* $P < 0.05$). Scatter dot plot values represent medians and [IQR]. **B** CSF miR-34a-3p levels are increased in familial ALS (fALS) compared to HC (** $P < 0.01$). **C** CSF miR-625-3p levels are higher in fALS compared

to HC (** $P < 0.01$) and in fALS compared to sporadic ALS (sALS) (**** $P < 0.001$). **D** ROC curve showed accuracy of CSF miR34a-3p levels in ALS vs. HC (* $P < 0.05$) and fALS vs. HC (** $P < 0.01$). **E** ROC curve showed accuracy of CSF miR-625-3p levels in fALS vs. HC (** $P < 0.01$) and in fALS vs. sALS (**** $P < 0.001$). **F** ROC curve showed accuracy of CSF miR-625-3p/miR-34a-3p pair in fALS vs. HC (non-significant)

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00018-022-04217-1>.

Acknowledgements The authors wish to thank Associazione Centro Dino Ferrari for support.

Author contributions MR and VM conceived and performed all the experiments. MR, ML and DR provided cell culture data. RS performed karyotype analysis. VM performed molecular biology experiments and data analysis, while LD carried out TLDA assays. DR and FB performed bioinformatics analysis. DG, MM, PM, KP and PVD collected CSF samples. MR, VM, PM and NH conducted qPCR experiments on CSF. DG analyzed CSF data and performed all the statistical analysis. MR, MN, DG and VM wrote the manuscript. MR produced Figures. SC and MN conceived the project, designed the research and reviewed the draft. NB, GPC, VB and PVD provided resources. All authors edited and gave critical input on the manuscript, providing data interpretation and contribution to the final version of the manuscript.

Funding This study was supported by Fondazione Italiana di Ricerca per la SLA, AriSLA (to SC, smallRNALS), Fondazione Regionale per la Ricerca Biomedica, FRRB (to GPC, TransALS), Italian Ministry of Health Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Ricerca Corrente 2020 RC245 to GPC and NB, E-Rare3 JTC2018 Integrals to SC and PVD, Italian Ministry of Health RF-2013-02355764 to GPC. PVD holds a senior clinical investigatorship of FWO-Vlaanderen and is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, the ALS Liga België and the KU Leuven funds “Een Hart voor ALS”, “Laeversfonds voor ALS Onderzoek” and the “Valéry Perrier Race against ALS Fund”.

Availability of data and material All data generated or analysed during this study are included in this published article [and its supplementary information files].

Declarations

Conflict of interest The authors report no competing interests.

Ethics approval The studies involving human samples were conducted in accordance with the ethical standards of the Declaration of Helsinki and with national legislation and institutional guidelines. Human fibroblast cell lines were obtained from Eurobiobank with informed consent approved by the ethical committee at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan. All subjects provided written informed consent approved by the local ethical committee for the collection, storage and analysis of CSF samples (0,004,520, S50354, S55312, S59552). This experimental study was conducted in accordance with the international GLP and GCP guidelines.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will

need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References


1. Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. *N Engl J Med* 377:162–172. <https://doi.org/10.1056/NEJMra1603471>
2. Wobst HJ, Mack KL, Brown DG et al (2020) The clinical trial landscape in amyotrophic lateral sclerosis—past, present, and future. *Med Res Rev* 40:1352–1384. <https://doi.org/10.1002/med.21661>
3. DeJesus-Hernandez M, Mackenzie IR, Boeve BF et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 72:245–256. <https://doi.org/10.1016/j.neuron.2011.09.011>
4. Renton AE, Majounie E, Waite A et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72:257–268. <https://doi.org/10.1016/j.neuron.2011.09.010>
5. Rosen DR, Siddique T, Patterson D et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* 362:59–62. <https://doi.org/10.1038/362059a0>
6. Sreedharan J, Blair IP, Tripathi VB et al (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* 319:1668–1672. <https://doi.org/10.1126/science.1154584>
7. Kwiatkowski TJ, Bosco DA, Leclerc AL et al (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* 323:1205–1208. <https://doi.org/10.1126/science.1166066>
8. Vance C, Rogelj B, Hortobágyi T et al (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science* 323:1208–1211. <https://doi.org/10.1126/science.1165942>
9. Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. *Eur J Neurol* 27:1918–1929. <https://doi.org/10.1111/ene.14393>
10. Lagier-Tourenne C, Polymenidou M, Cleveland DW (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. *Hum Mol Genet* 19:R46–64. <https://doi.org/10.1093/hmg/ddq137>
11. Kawahara Y, Mieda-Sato A (2012) TDP-43 promotes microRNA biogenesis as a component of the drosha and dicer complexes. *Proc Natl Acad Sci USA* 109:3347–3352. <https://doi.org/10.1073/pnas.1112427109>
12. Freischmidt A, Müller K, Ludolph AC, Weishaupt JH (2013) Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. *Acta Neuropathol Commun* 1:42. <https://doi.org/10.1186/2051-5960-1-42>
13. Dini Modigliani S, Morlando M, Errichelli L et al (2014) An ALS-associated mutation in the FUS 3'-UTR disrupts a microRNA–FUS regulatory circuitry. *Nat Commun* 5:4335. <https://doi.org/10.1038/ncomms5335>
14. Olejniczak M, Kotowska-Zimmer A, Krzyzosiak W (2018) Stress-induced changes in miRNA biogenesis and functioning. *Cell Mol Life Sci* 75:177–191. <https://doi.org/10.1007/s00018-017-2591-0>
15. Caputo D, Colantoni A, Lu L et al (2018) A regulatory circuitry between Gria2, miR-409, and miR-495 is affected by ALS FUS mutation in ESC-derived motor neurons. *Mol Neurobiol* 55:7635–7651. <https://doi.org/10.1007/s12035-018-0884-4>

16. Zhang T, Wu YC, Mullane P et al (2018) FUS regulates activity of microRNA-mediated gene silencing. *Mol Cell* 69:787–801.e8. <https://doi.org/10.1016/j.molcel.2018.02.001>
17. Paez-Colasante X, Figueroa-Romero C, Rumora AE et al (2020) Cytoplasmic TDP43 binds microRNAs: new disease targets in amyotrophic lateral sclerosis. *Front Cell Neurosci* 14:117
18. Zuo X, Zhou J, Li Y et al (2021) TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. *Nat Struct Mol Biol* 28:132–142. <https://doi.org/10.1038/s41594-020-00537-7>
19. Huntzinger E, Izaurralde E (2011) Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nat Rev Genet* 12:99–110. <https://doi.org/10.1038/nrg2936>
20. Fineberg SK, Kosik KS, Davidson BL (2009) MicroRNAs potentiate neural development. *Neuron* 64:303–309. <https://doi.org/10.1016/j.neuron.2009.10.020>
21. Nowak JS, Michlewski G (2013) miRNAs in development and pathogenesis of the nervous system. *Biochem Soc Trans* 41:815–820. <https://doi.org/10.1042/BST20130044>
22. Jużwik CA, DrakeZhang SY et al (2019) microRNA dysregulation in neurodegenerative diseases: a systematic review. *Prog Neurobiol* 182:101664. <https://doi.org/10.1016/j.pneurobio.2019.101664>
23. Rashed MH, Bayraktar E, Helal GK et al (2017) Exosomes: from garbage bins to promising therapeutic targets. *Int J Mol Sci*. <https://doi.org/10.3390/ijms18030538>
24. McKelvey KJ, Powell KL, Ashton AW et al (2015) Exosomes: mechanisms of uptake. *J Circ Biomark* 4:7. <https://doi.org/10.5772/61186>
25. Simons M, Raposo G (2009) Exosomes–vesicular carriers for intercellular communication. *Curr Opin Cell Biol* 21:575–581. <https://doi.org/10.1016/jceb.2009.03.007>
26. Thakur BK, Zhang H, Becker A et al (2014) Double-stranded DNA in exosomes: a novel biomarker in cancer detection. *Cell Res* 24:766–769. <https://doi.org/10.1038/cr.2014.44>
27. Dardiotis E, Aloizou A-M, Siokas V et al (2018) The role of MicroRNAs in patients with amyotrophic lateral sclerosis. *J Mol Neurosci* 66:617–628. <https://doi.org/10.1007/s12031-018-1204-1>
28. Emde A, Eitan C, Liou L-L et al (2015) Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. *EMBO J* 34:2633–2651. <https://doi.org/10.15252/embj.201490493>
29. Rinchetti P, Rizzuti M, Faravelli I, Corti S (2018) MicroRNA metabolism and dysregulation in amyotrophic lateral sclerosis. *Mol Neurobiol* 55:2617–2630. <https://doi.org/10.1007/s12035-017-0537-z>
30. Rao P, Benito E, Fischer A (2013) MicroRNAs as biomarkers for CNS disease. *Front Mol Neurosci* 6:39. <https://doi.org/10.3389/fnmol.2013.00039>
31. Ricci C, Marzocchi C, Battistini S (2018) MicroRNAs as biomarkers in amyotrophic lateral sclerosis. *Cells* 7:E219. <https://doi.org/10.3390/cells7110219>
32. Joilin G, Leigh PN, Newbury SF, Hafezparast M (2019) An overview of microRNAs as biomarkers of ALS. *Front Neurol* 10:186
33. Wang L, Zhang L (2020) Circulating exosomal miRNA as diagnostic biomarkers of neurodegenerative diseases. *Front Mol Neurosci* 13:53. <https://doi.org/10.3389/fnmol.2020.00053>
34. Dasgupta I, Chatterjee A (2021) Recent advances in miRNA delivery systems. *Methods Protoc* 4:10. <https://doi.org/10.3390/mps4010010>
35. Maury Y, Côme J, Piskowski RA et al (2015) Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. *Nat Biotechnol* 33:89–96. <https://doi.org/10.1038/nbt.3049>
36. Pergoli L, Cantone L, Favero C et al (2017) Extracellular vesicle-packaged miRNA release after short-term exposure to particulate matter is associated with increased coagulation. *Part Fibre Toxicol* 14:32. <https://doi.org/10.1186/s12989-017-0214-4>
37. Butovsky O, Siddiqui S, Gabrieli G et al (2012) Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. *J Clin Invest* 122:3063–3087. <https://doi.org/10.1172/JCI62636>
38. Benigni M, Ricci C, Jones AR et al (2016) Identification of miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis patients. *Neuromolecular Med* 18:551–560. <https://doi.org/10.1007/s12017-016-8396-8>
39. Kong X, Zhai J, Yan C et al (2019) Recent advances in understanding FOXN3 in breast cancer, and other malignancies. *Front Oncol* 9:234. <https://doi.org/10.3389/fonc.2019.00234>
40. Antar LN, Li C, Zhang H et al (2006) Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. *Mol Cell Neurosci* 32:37–48. <https://doi.org/10.1016/j.mcn.2006.02.001>
41. Figueroa-Romero C, Hur J, Bender DE et al (2012) Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. *PLoS ONE* 7:e252672. <https://doi.org/10.1371/journal.pone.0052672>
42. Bucchia M, Ramirez A, Parente V et al (2015) Therapeutic development in amyotrophic lateral sclerosis. *Clin Ther* 37:668–680. <https://doi.org/10.1016/j.clinthera.2014.12.020>
43. Chiò A, Mazzini L, Mora G (2020) Disease-modifying therapies in amyotrophic lateral sclerosis. *Neuropharmacology* 167:107986. <https://doi.org/10.1016/j.neuropharm.2020.107986>
44. Amado DA, Davidson BL (2021) Gene therapy for ALS: a review. *Mol Ther* 29:3345–3358. <https://doi.org/10.1016/j.ymthe.2021.04.008>
45. Allodi I, Comley L, Nichterwitz S et al (2016) Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS. *Sci Rep* 6:25960. <https://doi.org/10.1038/srep25960>
46. Laneve P, Tollis P, Caffarelli E (2021) RNA deregulation in amyotrophic lateral sclerosis: the noncoding perspective. *Int J Mol Sci* 22:10285. <https://doi.org/10.3390/ijms221910285>
47. Butti Z, Patten SA (2018) RNA dysregulation in amyotrophic lateral sclerosis. *Front Genet* 9:712. <https://doi.org/10.3389/fgene.2018.00712>
48. Pham J, Keon M, Brennan S, Saksena N (2020) Connecting RNA-modifying similarities of TDP-43, FUS, and SOD1 with microRNA dysregulation amidst a renewed network perspective of amyotrophic lateral sclerosis proteinopathy. *Int J Mol Sci* 21:E3464. <https://doi.org/10.3390/ijms21103464>
49. Campos-Melo D, Droppelmann CA, He Z et al (2013) Altered microRNA expression profile in amyotrophic lateral sclerosis: a role in the regulation of NFL mRNA levels. *Mol Brain* 6:26. <https://doi.org/10.1186/1756-6606-6-26>
50. De Felice B, Annunziata A, Fiorentino G et al (2014) miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. *Neurogenetics* 15:243–253. <https://doi.org/10.1007/s10048-014-0420-2>
51. Figueroa-Romero C, Hur J, Lunn JS et al (2016) Expression of microRNAs in human post-mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. *Mol Cell Neurosci* 71:34–45. <https://doi.org/10.1016/j.mcn.2015.12.008>
52. De Felice B, Manfellotto F, Fiorentino G et al (2018) Wide-ranging analysis of microRNA profiles in sporadic amyotrophic lateral sclerosis using next-generation sequencing. *Front Genet* 9:310
53. Rizzuti M, Filosa G, Melzi V et al (2018) MicroRNA expression analysis identifies a subset of downregulated miRNAs in ALS motor neuron progenitors. *Sci Rep* 8:10105. <https://doi.org/10.1038/s41598-018-28366-1>
54. Helferich AM, Brockmann SJ, Reinders J et al (2018) Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic

- and familial ALS. *Cell Mol Life Sci* 75:4301–4319. <https://doi.org/10.1007/s00018-018-2873-1>
55. Loffreda A, Nizzardo M, Arosio A et al (2020) miR-129-5p: a key factor and therapeutic target in amyotrophic lateral sclerosis. *Prog Neurobiol* 190:101803. <https://doi.org/10.1016/j.pneurobio.2020.101803>
 56. Gagliardi D, Comi GP, Bresolin N, Corti S (2019) MicroRNAs as regulators of cell death mechanisms in amyotrophic lateral sclerosis. *J Cell Mol Med* 23:1647–1656. <https://doi.org/10.1111/jcmm.13976>
 57. Vishnoi A, Rani S (2017) MiRNA biogenesis and regulation of diseases: an overview. *Methods Mol Biol* 1509:1–10. https://doi.org/10.1007/978-1-4939-6524-3_1
 58. Volonte C, Apolloni S, Parisi C (2015) MicroRNAs: newcomers into the ALS picture. *CNS Neurol Disord Drug Targets* 14:194–207. <https://doi.org/10.2174/1871527314666150116125506>
 59. Akbari Dilmaghani N, Hussien BM, Nateghinia S et al (2021) Emerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis. *Metab Brain Dis* 36:737–749. <https://doi.org/10.1007/s11011-021-00697-5>
 60. Agostini M, Tucci P, Steinert JR et al (2011) microRNA-34a regulates neurite outgrowth, spinal morphology, and function. *PNAS* 108:21099–21104. <https://doi.org/10.1073/pnas.1112063108>
 61. Wang X, Liu P, Zhu H et al (2009) miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. *Brain Res Bull* 80:268–273. <https://doi.org/10.1016/j.brainresbull.2009.08.006>
 62. Zhou F, Zhang C, Guan Y et al (2018) Screening the expression characteristics of several miRNAs in G93A-SOD1 transgenic mouse: altered expression of miRNA-124 is associated with astrocyte differentiation by targeting Sox2 and Sox9. *J Neurochem* 145:51–67. <https://doi.org/10.1111/jnc.14229>
 63. Catanesi M, d'Angelo M, Tupone MG et al (2020) MicroRNAs dysregulation and mitochondrial dysfunction in neurodegenerative diseases. *Int J Mol Sci*. <https://doi.org/10.3390/ijms21175986>
 64. De Luna N, Turon-Sans J, Cortes-Vicente E et al (2020) Down-regulation of miR-335-5P in amyotrophic lateral sclerosis can contribute to neuronal mitochondrial dysfunction and apoptosis. *Sci Rep* 10:4308. <https://doi.org/10.1038/s41598-020-61246-1>
 65. Capitano F, Camon J, Licursi V et al (2017) MicroRNA-335-5p modulates spatial memory and hippocampal synaptic plasticity. *Neurobiol Learn Mem* 139:63–68. <https://doi.org/10.1016/j.nlm.2016.12.019>
 66. You Y, Ikezu T (2019) Emerging roles of extracellular vesicles in neurodegenerative disorders. *Neurobiol Dis* 130:104512. <https://doi.org/10.1016/j.nbd.2019.104512>
 67. Ding X-M, Zhao L-J, Qiao H-Y et al (2019) Long non-coding RNA-p21 regulates MPP+-induced neuronal injury by targeting miR-625 and derepressing TRPM2 in SH-SY5Y cells. *Chem Biol Interact* 307:73–81. <https://doi.org/10.1016/j.cbi.2019.04.017>
 68. Malko P, Syed Mortadza SA, McWilliam J, Jiang L-H (2019) TRPM2 channel in microglia as a new player in neuroinflammation associated with a spectrum of central nervous system pathologies. *Front Pharmacol* 10:239. <https://doi.org/10.3389/fphar.2019.00239>
 69. Kovanda A, Leonardis L, Zidar J et al (2018) Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age-matched controls. *Sci Rep* 8:5609. <https://doi.org/10.1038/s41598-018-23139-2>
 70. Weber JA, Baxter DH, Zhang S et al (2010) The microRNA spectrum in 12 body fluids. *Clin Chem* 56:1733–1741. <https://doi.org/10.1373/clinchem.2010.147405>
 71. De Felice B, Guida M, Guida M et al (2012) A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. *Gene* 508:35–40. <https://doi.org/10.1016/j.gene.2012.07.058>
 72. Cloutier F, Marrero A, O'Connell C, Morin PJ (2015) MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis. *J Mol Neurosci* 56:102–112. <https://doi.org/10.1007/s12031-014-0471-8>
 73. Waller R, Wyles M, Heath PR et al (2017) Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs related to neural and glial activity. *Front Neurosci* 11:731. <https://doi.org/10.3389/fnins.2017.00731>
 74. Sheinerman KS, Toledo JB, Tsivinsky VG et al (2017) Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. *Alzheimers Res Ther* 9:89. <https://doi.org/10.1186/s13195-017-0316-0>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Mafalda Rizzuti¹ · Valentina Melzi¹ · Delia Gagliardi² · Davide Resnati² · Megi Meneri¹ · Laura Dioni³ · Pegah Masrori^{4,5} · Nicole Hersmus⁴ · Koen Poesen⁶ · Martina Locatelli² · Fabio Biella² · Rosamaria Silipigni⁷ · Valentina Bollati³ · Nereo Bresolin^{1,2} · Giacomo Pietro Comi^{1,2,8} · Philip Van Damme^{4,5} · Monica Nizzardo¹ · Stefania Corti^{1,2} 

¹ Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy

² Department of Physiopathology and Transplants, Dino Ferrari Center, University of Milan, via Francesco Sforza 35, 20122 Milan, Italy

³ EPIGET LAB, Unit of Occupational Medicine, Department of Clinical Sciences and Community Health, University of Milan, IRCCS Ca' Granda Foundation Ospedale Maggiore Policlinico, Milan, Italy

⁴ Department of Neurosciences, Laboratory of Neurobiology, Center for Brain and Disease, KU Leuven, University of Leuven, Leuven, Belgium

⁵ Neurology Department, University Hospitals Leuven, Leuven, Belgium

⁶ Department of Neurosciences, Laboratory for Molecular Neurobiomarker Research, Leuven Brain Institute, KU Leuven, 3000 Leuven, Belgium

⁷ Laboratory of Medical Genetics, IRCCS Ca' Granda Foundation Ospedale Maggiore Policlinico, Milan, Italy

⁸ Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neuromuscular and Rare Diseases Unit, Milan, Italy